Chapter 15 : Treatment of Osteomyelitis and Septic Arthritis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Treatment of Osteomyelitis and Septic Arthritis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap15-1.gif /docserver/preview/fulltext/10.1128/9781555817817/9781555812317_Chap15-2.gif


This chapter summarizes the current knowledge of the use of quinolones in the treatment of osteomyelitis and septic arthritis. The identification of the causative organisms of osteomyelitis is essential for diagnosis and treatment. It is important to obtain deep specimens, in particular by bone biopsy, for microbiological and pathological analysis. The specific organism isolated in bacterial osteomyelitis is often associated with the age of the patient, a common clinical presentation (i.e., trauma or recent surgery), and the presence or absence of vascular insufficiency. is found in most patients with acute hematogenous osteomyelitis. , , , ( and ) are commonly isolated in patients with chronic osteomyelitis. The rabbit model of chronic osteomyelitis has the relative advantage of assessing the rate of negative microbiological cultures after 3 to 4 weeks of therapy. Several recent studies show interesting results concerning the potential utilization of quinolones in local drug-carrier systems that allow high local antibiotic concentrations to be achieved. Several recent reviews of the use of various agents in the therapy of osteomyelitis have reported that among the quinolones presently available, ciprofloxacin, ofloxacin, and pefloxacin have been used most often in large series of patients with bacterial osteomyelitis. The combination of quinolones with rifampin for the treatment of staphylococcal osteomyelitis appears promising.

Citation: Bernard L, Waldvogel F, Lew D. 2003. Treatment of Osteomyelitis and Septic Arthritis, p 251-258. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch15
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1. Bayer, A. S.,, D. Norman,, and D. Anderson. 1985. Efficacy of ciprofloxacin in experimental arthritis caused by Escherichia coli —in vitro-in vivo correlations. J. Infect. Dis. 152:811816.
2. Bouchenaki, N.,, P. E. Vaudaux,, E. Huggler,, F. A. Waldvogel,, and D. P. Lew. 1990. Successful single-dose prophylaxis of Staphylococcus aureus foreign body infections in guinea pigs by fleroxacin. Antimicrob. Agents Chemother. 34:2124.
3. Bouza, E.,, and P. Munoz. 1999. Micro-organisms responsible for osteoarticular infections. Baillieres Best Pract. Res. Clin. Rheumatol. 13:2135.
4. Brouqui, P.,, M. C. Rousseau,, A. Stein,, M. Drancourt,, and D. Raoult. 1995. Treatment of Pseudomonas aeruginosa-'mfect ed orthopedic prostheses with ceftazidime-ciprofloxacin antibiotic combination. Antimicrob. Agents Chemother. 39:24232425.
5. Carek, P. J.,, L. M. Dickerson,, and J. L. Sack. 2001. Diagnosis and management of osteomyelitis. Am. Earn. Physician 63:24132412.
6. Chuard, C., , M. Herrmann,, P. Vaudaux, F. A.,, Waldvogel,, and D. P. Lew. 1991. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob. Agents Chemother. 35:26112616.
7. Cierny, G.,, J. T. Mader,, and H. Pennick. 1985. A clinical staging system of adult osteomyelitis system. Contemp. Orthop. 10:1737.
8. Coignard, S.,, C. Renard,, and A. Lortat-Jacob. 1986. Diffusion de la pefloxacine dans le tissu osseux humain. Med. Mai. Infect. 7:471474.
9. Cremieux, A. C.,, A. S. Mghir,, R. Bleton,, M. Manteau,, N. Belmatoug,, L. Massias,, L. Garry,, N. Sales,, B. Maziere,, and C. Carbon. 1996. Efficacy of sparfloxacin and autoradiographic diffusion pattern of [1 4C]sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection. Antimicrob. Agents Chemother. 40:21112116.
10. Dan, M.,, Y. Siegman Igra,, S. Pitlik,, and R. Raz. 1990. Oral ciprofloxacin treatment of Pseudomonas aeruginosa osteomyelitis. Antimicrob. Agents Chemother. 34:849852.
11. Defino, H. L. A.,, J. E. Moretti,, and A. E. Rodrigues-Fuentes. 1992. Comparative study of the efficacy of pefloxacin versus cephalotin/cephalexin + gentamicin in the treatment of posttraumatic or post-surgical osteomyelitis. Rev. Bras. Med. 49:785790.
12. Dellamonica, P.,, E. Bernard,, H. Etesse,, and R. Garraffo. 1986. The diffusion ofpefloxacin into bone and the treatment of osteomyelitis. J. Antimicrob.Chemother. 17(Suppl. B):93102.
13. Desplaces, N.,, and J. F. Acar. 1988. New quinolones in thetreatment of joint and bone infections. Rev. Infect. Dis. 10(Suppl.1):S179S183.
14. Drancourt, M.,, A. Stein,, J. N. Argenson,, A. Zannier,, G. Curvale,, and D. Raoult. 1993. Oral rifampin plus ofloxacin for treatment of Staphylococcus-'mi ected orthopedic implants. Antimicrob. Agents Chemother. 37:12141218.
15. Dworkin, R.,, G. Modin,, S. Kunz,, R. Rich,, O. Zak,, and M. Sande. 1990. Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis. Antimicrob. Agents Chemother. 34:10141016.
16. Fong, I.W.,, W. H. Ledbetter,, A. C. Vandenbroucke,, M. Simbul,, and V. Rahm. 1986. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob. Agents Chemother. 29:405408.
17. Galanakis, N.,, H. Giamarellou,, T. Moussas,, E. Dounis. 1997. Chronic osteomyelitis caused by multi-resistant gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up. J. Antimicrob. Chemother. 39:241246.
18. Garcia Rosario, L. N.,, and C. H. Ramirez Ronda. 1990. The use of ciprofloxacin in patients with osteomyelitis associated with vascular insufficiency. Bol. Assoc. Med. P. R. 82:125128.
19. Gentry, L. O.,, and G. G. Rodriguez. 1990. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. Antimicrob. Agents Chemother. 34:4043.
20. Gentry, L. O. 1991. Oral antimicrobial therapy for osteomyelitis. Ann. Intern. Med. 114:986987.
21. Gentry, L. O.,, and G. G. Rodriguez. 1991. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob. Agents Chemother. 35:538541.
22. Gilbert, D. N.,, A. D. Tice,, P. K. Marsh,, P. C. Craven,, and L. C. Preheim. 1987. Oral ciprofloxacin therapy for chronic contiguous osteomyelitis caused by aerobic gram-negative bacilli. Am. J. Med. 82:254258.
23. Gomis, M.,, J . Barberan,, B. Sanchez,, S. Khorrami,, J . Borja,, and J . Garcia-Barbal. 1999. Oral ofloxacin versus parenteral imipenem-cilastatin in the treatment of osteomyelitis. Rev. Esp. Quimioter 12:2449.
24. Greenberg, R. N.,, D. J . Kennedy,, P. M. Reilly,, K. L. Luppen,, W. J . Weinandt,, M. R. Bollinger,, F. Aguirre,, F. Kodesch,, A. M. Saeed. 1987. Treatment of bone, joint, and soft-tissue infections with oral ciprofloxacin. Antimicrob. Agents Chemother. 31:151155.
25. Greenberg, R. N.,, M. T. Newman,, S. Shariaty,, and R. W. Pectol. 2000. Ciprofloxacin, lomefloxacin, or levofloxacin as treatment for chronic osteomyelitis. Antimicrob. Agents Chemother. 44:164166.
26. Greenberg, R. N.,, A. D. Tice,, P. K. Marsh,, P. C. Craven,, P. M. Reilly,, M. Bollinger,, and W. J. Weinandt. 1987. Randomized trial of ciprofloxacin compared with other antimicrobial therapy in the treatment of osteomyelitis. Am. J. Med. 82:266269.
27. Henry, N. K.,, M. S. Rouse,, A. L. Whitesell,, M. E. McConnell,, and W. R. Wilson. 1987. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am. J. Med. 82:7375.
28. Hessen, M. T.,, M. J . Ingerman,, D. H. Kaufman,, M. T. Hessen,, M. J. Ingerman,, D. H. Kaufman,, P. Weiner,, J . Santoro,, O. M. Korzeniowski,, J . Boscia,, M. Topiel,, L. M. Bush,, and D. Kaye.. 1987. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am. J. Med. 82:262265.
29. Hessen, M. T.,, and M. E. Levison. 1989. Ciprofloxacin for the treatment of osteomyelitis: a review. J. Foot Surg. 28:100105.
30. Hoogkamp-Korstanje, J. A.,, H. A. van Bottenburg,, J . van Bruggen,, J. S. Davidson,, S. J. Detmar,, W. de Graaf,, J. Rijnks,, J. F. Ypma,, D. F. de Zwart. 1989. Treatment of chronic osteomyelitis with ciprofloxacin. J. Antimicrob. Chemother. 23:427-432.
31. Huddleston, P. M.,, J. M. Steckelberg,, A. D. Hanssen,, M. S. Rouse,, M. E. Bolander,, and R. Patel. 2000. Ciprofloxacin inhibition of experimental fracture healing. J. Bone Joint Surg. 82:161173.
32. Kanellakopoulou, K.,, N. Galanakis,, E. J. Giamarellos- Bourboulis,, C. Rifiotis,, K. Papakostas,, A. Andreopoulos,, E. Dounis,, P. Karagianakos,, H. Giamarellou. 2000. Treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with a biodegradable system of lactic acid polymer releasing pefloxacin. J. Antimicrob. Chemother. 46:311314.
33. Ketterl, R.,, T. Beckurts,, B. Stubinger,, and B. Claudi. 1988. Use of ofloxacin in openfractures and in the treatment of posttraumatic osteomyelitis. J.Antimicrob. Chemother. 22(SupplC):S159S166.
34. Ketterl, R.,, W. Wittwer,, and T. Beckurts. 1995. Ofloxacin zur antibiotikatherapie bei der chronischen posttraumatischen Osteitis. Med. Welt. 46:505511.
35. Lew, D.P.,, and F. A. Waldvogel,. 1993. , p. 371379. In D. C. Hooper, and J. S. Wolfson (ed.), Quinolone Antimicrobial Agents, 2nd ed. American Society for Microbiology, Washington, D.C.
36. Lew, D.P.,, and F. A. Waldvogel. 1999. Quinolones andosteomyelitis: state-of-the-art. Drugs. 4958(Suppl. 2):S85100S91110.
37. Lew, D. P.,, and F. A. Waldvogel. 1997. Osteomyelitis. N. Engl. J. Med. 336:9991007.
38. Lipsky, B. A.,, P. D. Baker,, G. C. Landon,, and R. Fernau. 1997. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin. Infect. Dis. 24:643648.
39. Lipsky, B. A. 1997. Osteomyelitis of the foot in diabetic patients. Clin. Infect. Dis. 25:13181326.
40. Lucet, J. C.,, M. Herrmann,, P. Rohner,, R. Auckenthaler,, F. A. Waldvogel,, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:23122317.
41. Mader, J. T.,, J. S. Cantrell,, and J . Calhoun. 1990. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J. Bone Joint Surg. 72:104110.
42. Mader, J.T.,, C. Norden,, J . D. Nelson,, and G. B. Calandra. 1992. Evaluation of new anti-infective drugs for the treatment of osteomyelitis in adults. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15(Suppl. 1):S155S16.
43. Meissner, A.,, and K. Borner. 1993. Konzentration von Ciprofloxacin im Knochengewebe Concentration of Ciproloxacin in Bone Tissue. Akt. Traumatol. 23:8084.
44. Meissner, A.,, K. Borner,, and P. Koeppe. 1990. Concentrations of ofloxacin in human bone and in cartilage. J. Antimicrob. Chemother. 26(Suppl. D:6974.
45. Monzon, M.,, F. Garcia-Alvarez,, A. Lacleriga,, E. Gracia,, J . Leiva,, C. Oteiza,, and B. Amorena. 2001. A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment. J. Orthop. Res. 19:820826.
46. Nicolau, D. P.,, L. Nie,, P. R. Tessier,, H. P. Kourea,, and C. H. Nightingale. 1998. Prophylaxis of acute osteomyelitis with asorbable ofloxacin-impregnated beads. Antimicrob. Agents Chemother. 42:840842.
47. Nie, L.,, D. P. Nicolau,, P. R. Tessier,, H. P. Kourea,, B. D. Browner,, and C. H. Nightingale. 1998. Use of a bioabsorbable polymer for the delivery of ofloxacin during experimental osteomyelitis treatment. J. Orthop. Res. 16:7679.
48. Nix, D. E.,, T. J. Cumbo,, P. Kuritzky,, J. M. DeVito,, J. J. Schentag. 1987. Oral ciprofloxacin in the treatment of serious soft tissue and bone infections. Efficacy, safety, and pharmacokinetics. Am. J. Med. 82:146153.
49. Norden, C.,, J. D.Nelson,, J. T. Mader,, and G. B. C alandra. 1992. Evaluation of new anti-infective drugs for the treatment of infectious arthritis in adults. Infectious Diseases Society of America and the Food and Drug Administration. Clin. Infect. Dis. 15(Suppl. 1):S167S171.
50. Norden, C. W.,, and E. Stunners. 1995. Ciprofloxacin as therapy for experimental osteomyelitis caused by Pseudomonas aeruginosa. J. Infect. Dis. 151:291294.
51. Norrby, S.R. 1989. Ciprofloxacin in the treatment ofacute and chronic osteomyelitis: a review. Scand. J Infect. Dis.Suppl. 60(Suppl.):S74S78.
52. Ortega, M.,, A. Soriano,, S. Garcia,, M. Almela,, J. L. Alvarez,, X. Tomas,, J . Mensa,, and E. Soriano. 2000. Tolerability and safety of levofloxacin long-term treatment. Rev. Esp. Quimioter 13:263266.
53. Patzakis, M. J.,, R. S. Bains,, J. Lee,, L. Shepherd,, G. Singer,, R. Ressler,, F. Harvey,, and P. Holtom. 2000. Prospective, randomized, double-blind study comparing single-agent antibiotic therapy, ciprofloxacin, to combination antibiotic therapy in open fracture wounds. J. Orthop. Trauma. 14:529533.
54. Peterson, L. R.,, L. M. Lissack,, K. Canter,, C. E. Fasching,, C. Clabots,, D. N. Gerding. 1989. Therapy of lower extremity infections with ciprofloxacin in patients with diabetes mellitus, peripheral vascular disease, or both. Am. J. Med. 86:801808.
55. Rissing, J. P. 1997. Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones. Clin. Infect. Dis. 25:13271333.
56. Schlichting, C.,, C. Branger,, J. M. Fournier,, W. Witte,, A. Boutonnier,, C. Wolz,, P. Goullet,, and G. Doring. 1993. Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J. Clin. Microbiol. 31:227232.
57. Seibold, R.,, and A. Betz. 1991. Treatment of posttraumatic osteitis with intravenous ofloxacin. Clin. Ther. 13:457459.
58. Shirtliff, M. E.,, J. H. Calhoun,, and J. T. Mader. 2001. Comparative evaluation of oral levofloxacin and parenteral nafcillin in the treatment of experimental methicillin-susceptible Staphylococcus aureus osteomyelitis in rabbits. J. Antimicrob. Chemother. 48:253258.
59.SwedisStudyGroup. 1988. Therapy of acute and chronic gram-negative osteomyelitis withciprofloxacin. J. Antimicrob. Chemother. 22:221228.
60. Trujillo, I.Z.,, G. Valladares,, and A. Nava. 1993. Ciprofloxacin in the treatment of chronic osteomyelitis in adults. Drugs 45(Suppl. 3):S454S455.
61. Waldvogel, F.A. 1989. Use of quinolones for the treatmentof osteomyelitis and septic arthritis. Rev. Infect. Dis. 11:S1259S1263
62. Waldvogel, F. A.,, G. Medoff,, and M. N. Swartz. 1970. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N. Engl. J. Med. 29:2606.
63. Widmer, A. F.,, A. Gaechter,, P. E. Ochsner,, and W. Zimmerli. 1992. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin. Infect. Dis. 14:12511253.
64. Wispelwey, B.,, and W. M. Scheld. 1990. Ciprofloxacin in the treatment of Staphylococcus aureus osteomyelitis. A review. Diagn. Microbiol. Infect. Dis. 13:169171.
65. Wittmann, D.H.,, and E. Kotthaus. 1986. Further methodological improvement in antibiotic bone concentration measurements: penetration of ofloxacin into bone and cartilage. Infection 14(Suppl. 4):S270S273
66. Yamaguti, A.,, C. Trevisanello,, I. M. Lobo,, M. C. Carvano,, M. L. Bortoletto,, M. L. Silva,, R. Brasil Filho,, G. C. Levi,, and J . S. Mendonca. 1993. Oral ciprofloxacin for treatment of chronic osteomyelitis. Int. J. Clin. Pharmacol. Res. 13:7579.
67. Zimmerli, W.,, A. F. Widmer,, M. Blatter,, R. Frei,, P. E. Ochsner. 1998. Foreign-body infection (FBI) study group. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections—a randomized controlled trial. JAMA 279:15371541.


Generic image for table
Table 1

Spectrum of microorganisms responsible for osteomyelitis in adults

Citation: Bernard L, Waldvogel F, Lew D. 2003. Treatment of Osteomyelitis and Septic Arthritis, p 251-258. In Hooper D, Rubinstein E (ed), Quinolone Antimicrobial Agents, Third Edition. ASM Press, Washington, DC. doi: 10.1128/9781555817817.ch15

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error